Royal Bank of Canada
PDLI

Royal Bank of Canada’s PDL BioPharma, Inc. PDLI Stock Holding History

Royal Bank of Canada’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-16,713
Closed -$53K – 7547
2020
Q3 		$53K Buy
16,713
+4
+0% +$13 ﹤0.01% 5318
2020
Q2 		$49K Sell
16,709
-44,214
-73% -$140K ﹤0.01% 5234
2020
Q1 		$172K Sell
60,923
-10,003
-14% -$32.2K ﹤0.01% 4423
2019
Q4 		$230K Sell
70,926
-2,457,767
-97% -$7.13M ﹤0.01% 4543
2019
Q3 		$5.46M Sell
2,528,693
-635,380
-20% -$1.7M ﹤0.01% 2006
2019
Q2 		$9.94M Buy
3,164,073
+68,931
+2% +$224K ﹤0.01% 1568
2019
Q1 		$11.5M Buy
3,095,142
+179,482
+6% +$606K ﹤0.01% 1426
2018
Q4 		$8.45M Sell
2,915,660
-1,833
-0.1% -$5.04K ﹤0.01% 1614
2018
Q3 		$7.67M Buy
2,917,493
+3,307
+0.1% +$8.12K ﹤0.01% 1793
2018
Q2 		$6.82M Buy
2,914,186
+147,024
+5% +$410K ﹤0.01% 1797
2018
Q1 		$8.13M Sell
2,767,162
-43,680
-2% -$119K ﹤0.01% 1681
2017
Q4 		$7.7M Sell
2,810,842
-451,543
-14% -$1.39M ﹤0.01% 1778
2017
Q3 		$11.1M Sell
3,262,385
-146,968
-4% -$409K 0.01% 1460
2017
Q2 		$8.42M Sell
3,409,353
-64,603
-2% -$149K ﹤0.01% 1611
2017
Q1 		$7.89M Buy
3,473,956
+3,293,386
+1,824% +$7.29M ﹤0.01% 1623
2016
Q4 		$382K Sell
180,570
-95,312
-35% -$266K ﹤0.01% 3983
2016
Q3 		$925K Sell
275,882
-13,472
-5% -$42.8K ﹤0.01% 3167
2016
Q2 		$910K Buy
289,354
+18,053
+7% +$60.2K ﹤0.01% 3199
2016
Q1 		$903K Sell
271,301
-25,872
-9% -$80.7K ﹤0.01% 3150
2015
Q4 		$1.05M Sell
297,173
-481,952
-62% -$2.02M ﹤0.01% 3067
2015
Q3 		$3.92M Sell
779,125
-47,586
-6% -$273K ﹤0.01% 1735
2015
Q2 		$5.32M Sell
826,711
-98,094
-11% -$657K ﹤0.01% 1563
2015
Q1 		$6.51M Sell
924,805
-1,360,089
-60% -$9.85M ﹤0.01% 1441
2014
Q4 		$17.6M Buy
2,284,894
+420,500
+23% +$3.33M 0.01% 926
2014
Q3 		$13.9M Sell
1,864,394
-420,091
-18% -$3.9M 0.01% 1020
2014
Q2 		$22.1M Buy
2,284,485
+1,027,213
+82% +$9.16M 0.02% 752
2014
Q1 		$10.4M Buy
1,257,272
+290,456
+30% +$2.49M 0.01% 1128
2013
Q4 		$8.16M Buy
966,816
+140,795
+17% +$1.19M 0.01% 1320
2013
Q3 		$6.58M Buy
826,021
+7,946
+1% +$63.9K 0.01% 1401
2013
Q2 		$6.32M Buy
+818,075
New +$6.38M 0.01% 1303

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.39% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
HW
Hancock Whitney Gulfport, Mississippi $6B AUM 34.57% 1-Year Est. Return

Royal Bank of Canada's PDLI Position: Q4 2020 in Review

Royal Bank of Canada sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 16,713 shares — an estimated $53K sold.

Royal Bank of Canada first reported a position in PDLI in Q2 2013 and held it in 30 quarters. The position peaked at $22.1M in Q2 2014. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • Royal Bank of Canada reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • Royal Bank of Canada sold 16,713 PDL BioPharma, Inc. shares in Q4 2020, an estimated $53K.
  • Royal Bank of Canada first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 30 quarters.
  • Royal Bank of Canada's PDL BioPharma, Inc. position peaked at $22.1M in Q2 2014.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Royal Bank of Canada's 13F filing for Q4 2020, filed 16 Feb 2021.